A Time-Resolved Immunofluorometric Assay of Autoantibodies to Double-Stranded DNA by Veer, Gertjan van der Sluijs & Moens, Hein J. Bernelot
Eur J Clin Chem Clin Biochem 1996; 34:915-920 © 1996 by Walter de Gruyter · Berlin · New York
A Time-Resolved Immunofluorooietric Assay of Autoantibodies
to Double-Stranded DNA
Gertjan van der Sluijs Veer1 and Hein J. Bernelol Moens2
1
 Laboratorium
2
 Afdeling Reumatologie
Medisch Spectrum Twente, Enschede, The Netherlands
Summary: A time-resolved immunofluorometric assay (TRIFMA) of autoantibodies to double-stranded DNA
(dsDNA) is described. Biotinylated DNA was bound to the polystyrene solid phase coated with streptavidin. F(ab')2
fragments from antibodies raised in rabbits to human IgG were labelled with Eu3+, and used in the assay to label
the bound autoantibodies to dsDNA. The measuring range covers three decades. The proposed assay has good
analytical properties.
For calibration the First International Standard for antibodies to double-stranded DNA Wo/80 was used. The 97.5th
percentile in normal persons is 20 kIU/1. Comparison of the TRIFMA and the Farr-assay in the analysis of 56 sera
from 20 patients with systemic lupus erythematosus or lupus-like disease, 13 with other autoimmune diseases, and
10 blood-bank donors indicates a high degree of concordance (KendaWs τ = 0.56, ρ < 0.001).
Further evaluation in 102 patients with systemic lupus erythematosus, lupus-like disease and other autoimmune
diseases shows that sensitivity for active classical systemic lupus erythematosus is adequate, and specificity is excel-
lent.
Introduction
The measurement of antibodies with reactivity to
double-stranded DNA (dsDNA) is important for estab-
lishing the diagnosis of systemic lupus erythematosus
and in monitoring the disease (1,2).
Many techniques have been developed for detection and
estimation of autoantibodies to dsDNA. The most com-
monly used today being:
1. indirect immunofluorescence on the kinetoplast of
Crithidia luciliae,
2. precipitation of the complexes formed with radiola-
belled DNA (e. g. the Farr-assay), and
3. the enzyme-linked immunosorbent assay (ELISA)
(3).
In general the comparability between the techniques is
poor, even when the same reference preparation is used
as a 'standard'. This is caused by the polyclonal nature
of the autoantibodies, which can be of different avidity
and isotype, both in an individual as well as in the refer-
ence preparation. Various methods have different sensi-
tivities for various parts of the spectrum of antibodies
present. All methods lack analytical specificity (4). In
the CnYAfrf/a-test, anti-histone antibodies can cause
false-positive results (5). A further drawback of this test
is its seiniquantitative and subjective interpretation. Dis-
advantages of the Farr-assay are the limited measuring
range, the non-linearity (6), and the use of radioactivity.
In the conventional ELISA the precoating of the solid
phase, e. g. with protamine sulphate, necessary to make
DNA-antigen bind to it, causes 10—20% of the positive
responses to be false by binding a variety of protein
complexes (3, 7, 8). A different approach was therefore
suggested by Emlen et al.: dsDNA was biotinylated by
a photochemical process and bound to a streptavidin-
coated solid phase (7). This method has been claimed to
have a better clinical specificity than the classical
ELISA (7, 8). Unfortunately, patient-dependent non-spe-
cific binding has been described in this system as well,
the nature of which is unknown so far (3, 7). They ne-
cessitate the subtraction of blanks for each sample.
In our laboratory the technique of the time-resolved im-
munofluorometric assay (TRIFMA) (9), as used in the
Delfia™ system (Wallac, Turku, Finland), shows good
precision, an extended measuring range in comparison
with the corresponding ELISAs, and good possibilities
for automation (10).
It was decided to combine the advantages of the
TRIFMA with the biotin-streptavidin technique for
binding the dsDNA to the plate. Because it is known
that the anti-dsDNA autoantibodies of the isotype IgG
are clinically the most useful (4, 7), it was decided to
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focus on an anti-IgG label. Finally, the clinical signifi-
cance and usefulness of the TRIFMA were evaluated in
sera from systemic lupus erythematosus patients, other
patients and controls.
This stock was stored at -20 °C. The shelf life under this condi-
tion, in the presence of 1 g/1 bovine albumin as a stabilizer, was at
least one year. This preparation was diluted before use to a final
antibody concentration of 2.5 mg/1 in assay buffer. The reagent was
filtered before use through a 0.2 μιη filter FP030/30 (Schleicher &
Schuell, Dassel, Germany).
Materials and Methods
Reagents
TRIS-buffer: 0.15 mol/1 NaCl, 0.02 mol/1 TRIS, pH 7.8, 0.8
mmol/1 NaN3.
Washing buffer: 0.2 ml Tween-20™ (Merck, Darmstadt, Germany)
was added to 1 1 TRIS-buffer.
Assay buffer: 5 g/1 bovine albumin (Sigma, St. Louis MO, USA
Product No. A 9647) in washing buffer and filtered through paper
(Machery-Nagel, Diiren, Germany) before use.
Antigen
Two DNA preparations were tested:
1. plasmid double-stranded DNA from E. coli (2.3 Χ 103 bases),
free from single stranded DNA and RNA, > 90% supercoiled (do-
nation from Amsterdam Medical Centre, The Netherlands)
2. plasmid pBR322-(l) (Life Technologies, Breda, The Nether-
lands).
Photobiotin (N-(4-azido-2-nitrophenyl)-N'-(3-biotinylaminoprop-
yl)-N'-methyl-l,3-propane-diamine acetate) (Sigma, St Louis MO,
USA, Product No. A 1935) was used for DNA biotinylation.
Biotinylation of DNA was carried out following the procedure de-
scribed by Forster et al. (11), slightly modified. In short: a mixture
of equal volumes of DNA (0.5 g/1) and Photobiotin (1 g/1) was
irradiated in a polypropylene cup for 20 min at a distance of 10 cm,
under a glass plate (Mercury discharge lamp: type HPLR-N 400 W,
Philips, Eindhoven, The Netherlands). Cooling was achieved by a
fan. Excess of photobiotin was removed by butanol-2 extraction.
The biotinylated DNA was precipitated with ammonium acetate
and ethanol for 15 min at -78 °C. After centrifugation (10 min,
10000 g) and removal of the supernatant, the pellet was dried in
the air and dissolved in a buffer (TRIS 10 mmol/1, EDTA 1 mmol/1,
pH 7.5) to a concentration of approximately 100 mg/1.
Emlen et al. and Hylkema have demonstrated that this procedure
does not affect the double strand character of the DNA (7, 8).
The solution was stored at 4 °C. The degree of biotinylation was
estimated by photometry from the absorbance quotient of A26o
(DNA) and A473 (Biotin). Before use the solution was diluted to
1 mg/1 in TRIS-buffer.
Subjects and samples
Calibrators
For the calibration the First International Standard for antibodies
to double-stranded DNA Wo/80 (Central Laboratory of the Nether-
lands Red Cross Blood Transfusion Service (CLB), Amsterdam,
The Netherlands), which contains 100 ϊϋ/vial by definition, was
used (13). This preparation was reconstituted in distilled water (0.5
ml/vial) and further diluted in assay buffer to a set of calibrating
solutions ranging from 0.1 to 20 kIU/1, corresponding to 5 to 1000
kJU/1 under assay conditions.
As a secondary calibrator a serum from patient X, suffering from
classical non-renal systemic lupus erythematosus was selected, di-
lutions of which showed a good parallelism with the Wo/80 (fig.
1). The autoantibody to dsDNA concentration was estimated as
342 kIU/1 in the TRIFMA.
The recently introduced Dutch Reference Preparation for autoanti-
bodies to dsDNA (Relares, CLB, Amsterdam, The Netherlands)
was also tested for its use as a secondary calibrator.
Control samples
For the estimation of the between-run precision, three pools of pa-
tient sera were prepared with respectively low (19 kIU/1), interme-
diate (40 kIU/1) and high (137 kIU/1) concentrations of autoanti-
bodies to dsDNA. Freeze-dried aliquots were stored at -80 °C,
and reconstituted before use.
Sera
For the comparison between the TRIFMA, the Crithidia-test and
the Fair-assay, and for the other studies described, 56 sera were
selected from 20 patients with a clinical diagnosis of systemic lu-
pus erythematosus (4 with and 7 without renal involvement, 18
sera) or lupus-like disease (9 patients, 15 sera). These patients ful-
filled at least 4 (systemic lupus erythematosus) or 3 (lupus-like
disease) criteria for systemic lupus erythematosus other than the
presence of anti-DNA antibodies (1) (tab. 1). Also 13 sera were
obtained from patients with other autoimmune diseases (rheuma-
toid arthritis: 6, primary anti-phospholipid syndrome: 2, other: 5),
randomly selected from the rheumatological outpatient clinic
(n = 13, 4 <J, 9 $, age (range) 25-80 a), and 10 from blood-bank
donors.
Solid phase
Preparation of the microtitre plates (polystyrene Maxisorp™
(Nunc, Roskilde, Denmark)): plates were coated by overnight incu-
bation at 4 °C with 100 μΐ streptavidin (Sigma, St Louis MO, USA)
(5 mg/1 in TRIS-buffer) per well. Subsequently the plates were
washed once with washing buffer and the excess of fluid was re-
moved. To each well 100 μΐ biotinylated DNA solution was added,
followed by incubation for 2 h at room temperature. Plates were
washed six times with washing buffer.
Tracer
F(ab')2 fragments from antibodies raised in rabbits to human IgG
(Dako A/S, Glostrup, Denmark) were labelled with Eu3+, using
labelling reagent (Wallac Oy, Turku, Finland), containing N-l-(p-
isothiocyanatobenzyl)diethylene-triamine-N1,N2,N3,N3-tetraacetate.
The procedure and the method for estimating the labelling index
are described elsewhere (12).
A labelled antibody solution of 1.4 g/1 with a labelling index of
approximately 7 mol europium per mol antibody was obtained.
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Fig. 1 Parallelism of primary calibrator Wo/80 (O-), the serum
of patient X (used as secondary calibrator) (B—-), and Dutch Refer-
ence Preparation for autoantibodies to dsDNA (V···).
Van der Sluijs Veer and Bernelot Mo ens: Immunoassay of autoantibodies to dsDNA 917
Sera from blood-bank donors (n = 66, 39 <ί, 27 ?t age (mean
± SD) 42 ± 12 a) were used for establishing the reference interval.
To investigate specificity and interference, 18 sera from patients
with rheumatoid arthritis (rheumatoid factor (IgM) > 10 times the
upper limit of the reference interval) were tested.
AJ1 sera were stored at -20 °C before analysis.
After finishing these studies, we evaluated the performance of the
TRJFMA under routine conditions: the results of all tests for auto-
antibodies to dsDNA requested by all the rheumalologists during
the year 1995 (in 211 sera from 102 patients) were grouped accord-
ing to their diagnosis and their content of autoantibodies to
dsDNA (TRIFMA).
Methods
17ie proposed TRIFMA
Immediately after preparing the solid phase, the assay procedure
was performed at room temperature and consisted of
1) incubation for 2 hours of the coated microtitre well with 100 μΐ
of the respective calibrator dilutions, samples (diluted 1 : 50 in as-
say buffer) or assay buffer (reagent blank) in duplicate,
2) six wash steps with washing buffer,
3) incubation with 100 μΐ of the labelled antibody,
4) six wash steps with washing buffer,
5) incubation for 15 min with 200 μΐ of the enhancement solution
(Pharmacia, Turku, Finland): containing 6.8 mmol/1 potassium hy-
drogen phthalate, 100 mmol/1 acetic acid, 50 μηηοΐ/ΐ tri-w-octyl-
phosphine oxide, 15 μηιοΐ/ΐ 2-naphthoyl-trifluoro-acetone and 1 g/1
Triton X-100, pH 3.2, followed by standing for 10 min,
6) measurement of the time-resolved fluorescence with the Arc us
Fluorometer, type 1232 (Wallac Oy, Turku, Finland).
All incubation steps were performed while shaking the microtitre
plates on a Delfia Plateshaker 1296-001 (Wallac, Turku, Finland)
in the position 'slow' (frequency: 950 min~'). To obtain the net sig-
nal, the blank signal of each calibrator or sample, measured by the
same procedure but omitting the coating with biotinylated DNA, was
subtracted from the signal of each calibrator resp. sample.
Other methods
For method comparison the autoantibody to dsDNA was also mea-
sured
1. by the Farr-assay (anti-DNA, Diagnostic Products Corporation,
Los Angeles CA, USA), according to the instructions of the manu-
facturer. However, the Wo/80 was used as the calibrator and not
the standards provided with the kit. For results exceeding the meas-
uring range (i.e. > 50 kIU/1) the result was calculated by an ex-
trapolation of concentrations measured in several dilutions in a nor-
mal (autoantibody to dsDNA negative) serum. Reference value:
< 3 kIU/1.
2. by the indirect immunofluorescence test on Crithidia luciliae
(anti human IgG) (Immunoconcepts, Sacramento CA, USA). Re-
sults were scored as negative, weak positive or positive. Reference
value: negative.
Statistics
The statistical comparison of methods was performed according to
Passing & Bablok (14) and by Kendall's rank correlation test.
Results
Reagent preparation
Antigen
The mean biotinylation index of the DNA was 1 mole-
was no substantial difference in behaviour between the
two DNA preparations tested in the TRIFMA.
Label
The mean labelling index (n = 3) was 7 mol Eu34"/mol
IgG (F(ab')2), (range 5-9 mol/mol).
Analy t ica l evaluat ion
Assay characteristics
The calibration curve (Wo/80) was linear from 5 to 500
kIU/1, with a small deflection for the higher values. A
typical standard curve is shown in figure 2.
The Dutch Reference Preparation (Relares, CLB, Am-
sterdam, The Netherlands) was tested. It was found to
contain 300 kIU/1 if assayed as a patient's serum in the
TRIFMA, i.e. in a 1 : 50 dilution. Since a lack of paral-
lelism (fig. 1) between the two preparations exists, each
dilution of the Dutch Reference Preparation would have
to be calibrated separately on the Wo/80 for use in a
calibration curve in the TRIFMA. In addition we tested
dilutions of more sera from systemic lupus erythemato-
sus patients, all showing a parallelism with the Wo/80
and our secondary calibrator (patient X's serum), but not
with the Dutch Reference Preparation.
Linearity was good when tested in the following way:
two sera with high autoantibody to dsDNA concentra-
tion (150 and 650 kIU/1 respectively) were diluted seri-
ally with
a) the assay buffer
b) a serum with a low concentration of antibodies to
dsDNA
c) a serum with a low concentration of autoantibodies
to dsDNA and a high concentration of rheumatoid
factor. These dilutions were assayed in the same way
as samples.
The lower detection limit was determined by replicate
analysis (n = 12) of the assay buffer. It was defined as
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the concentration of autoantibodies to dsDNA corre-
sponding to the mean + 3 SD response of the assay
buffer. The limit was found to be 1.7 kJU/1.
Within-run precision was estimated by measuring sera
with different autoantibody to .dsDNA concentration in
replicate (n = 20). The autoantibodies to dsDNA can
be measured at a precision of < 10% in the range 5
to 20 kIU/1, and < 6% in the range 20 to 1000 kIU/1.
The between-run precision was estimated by measuring
three pools of patient sera in duplicate in twenty runs. It
was found to be < 12%.
The correlation between the Fair-assay and the TRIFMA
was calculated by Kendall's test: Kendall's τ = 0.56,
ρ < 0.001. Results of the regression analysis are shown
in figure 3.
The relation between the proposed TRIFMA and the in-
direct immunofluorescence on Crithidia luciliae is
shown in figure 4.
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Fig. 3 Regression between concentrations of autoantibodies to
dsDNA measured by the Farr-assay (x) and by TRIFMA (y) for 56
sera. The regression line (according to Passing & Bablok (14))
was y = O.lSx - 1.5. Confidence intervals: slope: 0.59 to 1.25,
intercept: -2.5 to -0.05. Line of identity ( ).
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Fig. 4 Relation between concentrations of autoantibodies to
dsDNA measured by indirect immunofluorescence on Crithidia
luciliae and by TRIFMA.
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Fig. 5 Correlation of TRIFMA blank signal with total IgG con-
centration in 56 serum samples.
Non-specific effects
The influence of blocking the plates with albumin, a
common procedure in immuno assays, was examined.
There was only a small difference in blanks of plates
with and without an albumin blocking step, provided
that the assay-buffer contained albumin. Since precision
decreased with blocking, this step was abandoned.
The system shows non-specific binding, which is pa-
tient-dependent and even occurs in some normal per-
sons. Therefore, to prevent false positive results, blank
signals must be taken into account.
There was a significant correlation between the sample
blank signal and its total IgG (r = 0.64). The regression
is shown in figure 5. Hence an attempt was made to
suppress the supposed non-specific binding of IgG by
adding relatively high concentrations of rabbit and goat
globulins to the assay buffer: normal goat serum and
normal rabbit serum (CLB, Amsterdam, The Nether-
lands) up to protein concentrations of 8 g/L These
attempts were not successful: the specific and non-spe-
cific signals decreased to the same degree, individual
patients remaining significantly different in their blank
signals.
Clinical significance
In healthy blood-bank donors (n = 66) the reference
value was determined as < 20 kIU/1 (97.5 percentile).
In patients with classical systemic lupus erythematosus,
the Fair-assay and TRIFMA produced comparable re-
sults (tab. 1). Discordant results were found, mostly in
cases with autoantibody to dsDNA concentrations close
to the threshold values. The Fair results ranged between
4 and 55 kIU/1, those from the TRIFMA from 0 to 20
kIU/1).
The distribution of TRIFMA results for different diagno-
ses in all rheumatological patients tested for autoanti-
bodies to dsDNA in 1995 are shown in table 2.
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Tab. 1 Results of TRIFMA and Fair-assay in 3 patient groups.
Systemic lupus erythematosus
(renal involvement)
Systemic lupus erythematosus
(non-renal)
Lupus-like disease
Number of
patients
c?/9 (Sera)
0/4 (7)
2/5(11)
0/9(15)
Age range
(a)
21-76
25-67
15-49
Fair and
TRIFMA
concordant
Patients (Sera)
4(7)
2(2)
6(9)
Farr above,
TRIFMA within
reference value
Patients (Sera)
0(0)
3(6)
Tab. 2 Distribution of sera grouped according to clinical diagnosis and concentrations of autoantibodies
to dsDNA (TRIFMA) in 102 patients from the Department of Rheumatology.
Diagnosis Number
of sera
(patients)
Number of sera containing autoantibodies to dsDNA
20 kIU/1 21-50 kJU/1 51-100 kIU/1 > 100 kIU/1
Systemic lupus erythematosus
— renal
Systemic lupus erythematosus
— non-renal
Systemic lupus erythematosus
25 (5)
103(26)
3 (12%)
50 (48%)
4(15%)
26 (25%)
14(54%)
15(15%)
5(19%)
12(12%)
— discoid
Lupus-like disease
Rheumatoid arthritis
Other systemic autoimmune diseases
Other rheumatic diseases
4 (3)
5 (4)
27(24)
13(10)
33 (30)
4(100%)
4 (80%)
26 (96%)
13(100%)
32 (97%)
0
0
1 (4%)
0
1 0%)
0
1 (20%)
0
0
0
0
0
0
0
0
Discussion
Current methods for measurement of autoantibodies to
DNA have drawbacks, which in turn cause difficulties
in clinical interpretation. The proposed TRIFMA may
represent an advance by the introduction and combina-
tion of two improvements: the use of time-resolved de-
tection of an europium label and an alternative technique
for binding of the antigen to the solid phase.
The introduction of an europium label potentially ex-
tends the standard curve up to about three decades. This
obviates the need for retesting sera with high concentra-
tions of autoantibodies to dsDNA in different dilutions.
Moreover this offers the possibility of measuring longi-
tudinal series of samples without interference by dif-
ferent matrix effects.
Binding the DNA-antigen to the solid phase by a strep-
tavidin-biotin bridge yields an improvement in specific-
ity in assays for autoantibodies to dsDNA (7, 8).
Unfortunately the system shows non-specific binding to
polystyrene, presumably of IgG, which is patient-depen-
dent and even occurs in some normal persons, necessi-
tating subtraction of blank measurements. From the
point of view of efficiency, this is undesirable: logisti-
cally, the number of samples to be handled doubles and
two types of coating have to be used. Analytically, the
within-run precision deteriorates considerably, espe-
cially at low concentrations, by the statistical propaga-
tion of errors. Others have struggled with this phenome-
non as we did (3, 7), but so far no one seems to have
been successful in solving the problem of unspecific
binding. The only clue we found, was a significant cor-
relation of the blanks with total IgG in the sample. Ef-
forts to suppress this binding specifically by adding non-
immunoreactive globulins (goat and rabbit serum) were
not succesful.
Calibration in this type of assay is an illusion. This
is illustrated for instance by the difference in reference
values for the Fair-assay and the TRIFMA, both ex-
pressed in Wo/80 International Units. Another example
is the non-parallel behaviour of the Dutch reference
preparation for autoantibodies to dsDNA, in compari-
son with the Wo/80, using the same technique. These
phenomena are of course caused by the pluriformity
of the antibodies in the reference preparations as well
as in individuals. Each method measures its own part
of the spectrum of antibodies present in the sample. At
best, an international reference preparation can yield
comparability of results among centres if these use the
same method.
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Even so, a strong correlation was found between
the Fair-assay and TRIFMA (Kendall's τ = 0.56,
ρ < 0.001). Some individuals showed a relatively large
deviation from the calculated regression line. Emlen et
al. suggested that IgM antibodies could possibly be re-
sponsible for this finding, for they are reactive in the
Farr-assay but not in the TRIFMA (7). Since the pre-
sence of anti-DNA antibodies is an important criterion
for the diagnosis of systemic lupus erythematosus (1), it
is difficult to establish the sensitivity and specificity of
a new test for this analyte. We have, therefore, divided
the patients into groups based on criteria other than the
presence of anti-DNA antibodies. The data in our small
patient group indicate that the TRIFMA is concordant
with the Fair-assay in classical systemic lupus erythema-
tosus patients. In the case of less certain diagnostic cir-
cumstances, usually described as 'lupus-like disease',
we found normal values in 5 patients who had (mildly)
positive results in the Fair-assay. Although these data
may be interpreted as indicative of low sensitivity, the
clinical diagnosis of systemic lupus erythematosus was
indeed questionable in these patients, who had been fol-
lowed for 1-6 years. Therefore a higher specificity of
the TRIFMA can be considered. The assumption that
the new assay provides better discrimination between
systemic lupus erythematosus and non-systemic lupus
erythematosus needs further study in larger patient
groups.
Anti-DNA testing is perhaps even more important for
the follow-up of systemic lupus erythematosus patients
(2). Our present patient group included only a few pa-
tients in whom disease activity varied strongly during
the consecutive observations. In these cases the
TRIFMA paralleled the Farr-assay. The fact that a few
patients followed longitudinally showed a normal
TRIFMA result in periods of recovery, while the Farr-
assay remained marginally elevated, indicates a slightly
smaller sensitivity of the former.
However, the data from the cohort of 102 patients from
the Department of Rheumatology, who were routinely
tested during one year for autoantibodies to dsDNA (tab.
2), demonstrate adequate sensitivity, especially for renal
systemic lupus erythematosus, in combination with a
high specificity.
Conclusion
The proposed time-resolved immunofluorometric assay
of autoantibodies to double-stranded DNA has good an-
alytical properties, good sensitivity and excellent speci-
ficity. Features that make the test superior to the Farr-
assay are an extended measuring range, better linearity
and the use of a non-radioactive label. Further studies to
establish the predictive value of autoantibodies to
dsDNA measured are in progress.
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